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ABSTRACT 
 
Sjögren’s syndrome (SS) is an auto-immune (AI) mediated destruction of the 
major and minor salivary glands, and is the second most common AI disease in the 
United States.  Typical treatment palliative in nature and no treatment is available that 
will reverse or halt the progression of the disease process.   
SS poses many dental problems for affected patients due to a loss of the 
protective effects of the saliva, resulting in increased caries incidence.  However, 
whether SS patients are more at risk for periodontal disease is controversial.  Periodontal 
disease is a gram-negative bacterial infection that may or may not elicit an immune 
response resulting in the destruction of the attachment apparatus of the teeth.   
Toll-like receptors (TLRs) are highly conserved pattern recognition receptors 
found throughout the body.  TLR4 recognizes lipopolysaccharide (LPS) on gram 
negative bacteria, and is involved in mucosal immunity.  Many in vitro studies have 
reported an increased expression of TLR4 in both SS and periodontal disease.  Whether 
or not TLR4 is a contributor to the induction and/or progression of SS and/or periodontal 
disease is unknown.   
This cross-sectional study examined potential differences in concentration of 
TLR4 in serum and citric acid-stimulated saliva from patients with SS and healthy age-, 
sex-, and periodontal disease matched control patients.   
 Salivary function was stimulated with 5.0 mLs of 2% citric acid, and whole 
saliva samples were obtained.  Full-mouth clinical periodontal measurements were 
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recorded from 21 SS patients and 22 control patients.  Salivary and plasma TLR4 
concentrations were determined by enzyme-linked immunoassays in 20 patients per 
study group.  Collected data was statistically analyzed for its respective distribution.  
 No statistical differences in age, body mass index (BMI), salivary TLR4 
concentrations, or clinical periodontal measurements were evident between either group.  
Salivary flow rates were significantly lower (P<0.001) whereas plaque % (p=0.048) and 
serum TLR4 concentrations (p=0.011) were significantly higher in SS patients.  
 The present ﬁndings support a hypothesis that a hyper-inflammatory systemic 
state, as seen in SS patients, can independently raise serum TLR4 concentration in the 
absence of periodontal disease and may be important in the induction and / or 
progression of SS-mediated pathophysiology in affected patients.   
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
1.1  Sjögren's syndrome overview 
Sjögren’s syndrome (SS) is the second most common autoimmune disorder, 
behind rheumatoid arthritis.  In the United States, the prevalence is estimated at 2-4 
million people.  Like many other autoimmune diseases, SS affects women more than 
men with reported ratios above 9:1, with peri- and post-menopausal women most often 
affected.  SS is an autoimmune exocrinopathy and classically affects the lacrimal and 
salivary glands, resulting in dryness of the eyes and oral cavity; however, it is a systemic 
disorder and can affect any of the secretory tissues throughout the body.  SS is 
categorized as either primary or secondary, where primary SS occurs without the 
presence of another connective tissue or autoimmune disease and secondary SS occurs in 
concert with another connective tissue disease such as systemic scleroderma, rheumatoid 
arthritis, or systemic lupus erythematosus (SLE).  The reports of primary and secondary 
SS demonstrate an approximately even distribution of each type of SS in affected 
patients.(1)     
In SS, there are consistent dental findings related to autoimmune-mediated 
salivary dysfunction and share similar findings with other conditions characterized by 
salivary hypofunction.  Clinically, SS patients often present with a high caries rate, 
mucosal dryness, increased fungal infections, altered salivary flow rate, and often a 
painless enlargement of the salivary glands.  Following loss of normal salivary function, 
difficulties are almost always encountered with chewing, swallowing, and speaking.  
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Alterations in taste and subsequent compromises in nutrition coupled with the above 
mentioned findings lead to a decreased quality of life.(2)  Biopsies of minor salivary 
glands reveal changes consisting of an inflammatory cell infiltrate around periductal 
tissues with a resulting loss of acinar cells.(3)  Histologic analysis of the infiltrate reveals 
it to be composed mainly of lymphocytes, with T-lymphocytes predominating.  The 
pathologic outcome is a loss of functional acinar tissues resulting in a loss of secretory 
output and symptoms of oral dryness.(4) 
Non-oral manifestations of SS include dry eyes, other xeroses including dryness 
of the nasopharyngeal, vaginal, and respiratory alveolar membranes.  Also, renal 
disorders and muscle and joint inflammation are common findings.  Serum changes in 
SS patients, both primary and secondary, include a notable hypergammaglobulinenemia, 
elevated total protein and sedimentation rate, decreased white blood cell counts, 
persistent rheumatoid factors, and the autoantibodies anti-sicca-syndrome-A (anti-SS-
A/Ro), anti-sicca syndrome-B (anti-SS-B/La).  These changes are nonspecific, and occur 
in the majority of affected SS patients, but also are found to be elevated in other 
autoimmune conditions.  SS, especially primary SS, predisposes patients to lymphomas, 
with a 2000-4000% increased incidence of the neoplasm(s) compared to unaffected 
patients.(5)  In almost all cases, these tumors are mucosally associated lymphoid tissue 
(MALT) tumors and commonly involve the salivary glands themselves. 
The skin may be affected and display palpable or non-palpable purpura 
associated with cryoglobulianemia and/or hyperglobulinaemia.(6)  Also, some patients 
may display medium vessel pathology and present with urticarial vasculitis, necrosing 
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vasculitis, or thrombotic lesions of the more superficial veins and arteries.  Other 
epidermal associated findings include vitiligo, anetoderma, alopecia, cutaneous 
lymphomas, and xerosis.(7)   
Arthalgia and arthriris are in general similar to rheumatoid arthritis and SLE and 
are usually symmetrical in the affected joint type and location.(8)  Furthermore, some 
patients will also display an arthritic pattern consistent with erosive osteoarthritis.(9)  
Asymmetrical joint edema may suggest an additional process such as crystalline or 
infectious arthropathy.  Muscle pain (myalgia) and muscle weakness are frequent 
findings in SS patients.(10)  Polymyositis is often associated with sicca symptoms.  
Other conditions, such as polymyalgia rheumatic, myopathy, and myostitis due to 
medications should also be considered and treated appropriately.  Neurologic problems 
including vasculitis, thrombitic and/or paraneoplastic processes can also cause 
symptoms of weakness and generalized fatigue.  Analysis of acute-phase reactants, 
muscle enzymes, electromyography, or biopsy may be necessary if symptoms progress 
or are debilitating.  Also, fibromyalgia is a common finding associated with SS and may 
cause myalgia and weakness independently.(11)  
The most common presentation of pulmonary involvement in SS are interstitial 
pneumonitis and tracheobronchial sicca.(12)  Furthermore, SS patients can develop 
MALTs of the lung.(13)  Other common pulmonary findings include hypersensitivity of 
the lung and toxic effect of drugs (alkylating agents, methotrexate, etc) as well as 
bacterial and/or fungal pneumonia from opportunistic infections in immunosuppressed 
patients.(14)  Pneumonitis in patients receiving monoclonal antibody therapy 
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(infliximab, rituximab) have been reported and signs/symptoms of pneumonitis must be 
evaluated in patients on this medication regimen.(15, 16)  
Pulmonary hypertension and pericarditis are common findings in SS 
patients.  Alterations in cardiophysiologic function may also manifest in clinical 
examinations as abnormal findings in physiologic compensation for the Valsalva 
maneuver, heart-rate response to deep breathing, and heart-rate and blood-pressure 
response to standing are abnormal in some patients with SS.(17)  Also, the incidence of 
congenital heart block is higher in infants born to anti-SS positive mothers(18), however 
other auto-antibodies have been implicated in addition to anti-SS.(19, 20)   
The most common renal finding in SS patients is interstitial nephritis,(21) 
although hypokalaemic paralysis,(22) osteomalacia, and renal calculi may be found in 
addition.(23)  Loss of function of the kidneys should primarily be attributed to 
medications, such as chronic non-steroidal anti-inflammatory drugs 
(NSAIDs).(24)  Patients may develop glomerulonephritis associated with 
hyperglobulinaemia.  Specifically, antibodies to double-stranded DNA may require 
testing for amyloidosis, immune-complex disorder, and/or undiagnosed systemic lupus 
erythematosus.(25)  Other common findings of the renal system are interstitial cystitis 
that may be antagonized by large fluid intake in SS patients to treat chronic dry 
mouth.(26)   
The most common G/I complaint in SS patients is dysphagia due to a 
combination of xerostomia and esophageal dysfunction.(27)  Also, gastritis is common 
and patients complaining of this symptom should be tested and treated (if positive) for 
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Helicobacter pylori infection, as this bacterium has been positively associated with 
MALT lymphomas in SS patients.(28)  Primary biliary cirrhosis and celiac sprue may 
also be found in SS patients, and identification and treatment of these conditions in SS 
patients is important.(29)  
Hypothyroidism and hypofunction of the pituitary and adrenal gland axis are 
common endocrine findings in patients with SS.  10% of patients with autoimmune 
thyroiditis also have similar findings, and the differential diagnosis must be confirmed 
and treated appropriately.(30),(31)  Alterations in thyroid function may manifest as 
lethargy, loss of cognitive function, and generalized fatigue.   
The risk of developing lymphoma is about 40 times that in the general population 
in SS patiets, and consequently lymphoproliferative disease is a particular 
concern.(32)  Most lymphomas in SS patients are marginal-zone B-cell neoplasms that 
arose in extranodal and nodal sites, and were not associated with concomitant viral 
infection.(33)  However, case reports of lymphomas in SS patients associated with H. 
pylori(34)100, human herpes virus 6(35), human t-lymphotropic virus type I,(36) and 
Epstein-Barr virus.(37)  Usually, lymphoma is initially recognized as progressively 
enlarged parotid glands, regional or general lymphadenopathy, pulmonary infiltrates, 
hypergammaglobulinemia, hepatosplenomegaly, and vasculitis.  All of these are non-
specific findings, but should be treated with suspicion and serologic testing and/or 
biopsy should be performed to make a diagnosis and treated appropriately.   
Central and peripheral neurologic problems are reported in approximately 20% 
of SS patients.(38),(39)  Sensory neuropathies are typically the most common, and 
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epineural inflammatory changes are often evident on nerve biopsy 
samples.(40)  Asymmetrical motor and/or sensory neuropathy can signal vasculitis of 
blood vessels.(6)  The frequency of central demyelinating disease in SS patients appears 
to be similar to that in systemic lupus erythematosus,(41) and SS patients may display 
abnormal oligoclonal bands in the cerebrospinal fluid and abnormal brain MRI. 
The most common psychiatric disorder in SS patients are anxiety and 
depression.(42)  These symptoms commonly are a prelude to a formal diagnosis of 
SS.(43)  Subtle changes to cognitive function and memory may be evident in SS 
patients, and may coincide with abnormal positron emission tomography scans largely in 
the frontal lobe(44),(45).  Another extremely common finding in SS patients is 
generalized fatigue that does not improve with increased sleep.  As many as 30% of 
patients with SS are affected in this manner.  Much effort has been made to identifity a 
serologic marker that coincides with fatigue, however to date hemoglobin, erythrocyte 
sedimentation rate, and C-reactive protein levels did not predict fatigue.(46, 47)  
1.2  Treatment strategies 
Conventional treatment of SS has been aimed at improving flow from the 
affected glands.  Recommendations include staying well hydrated plus preventative 
therapy to reduce damage to the teeth and periodontium and include supplemental 
fluoride application, use of xylitol-containing gums and rinses, a diet low in acidic foods 
and refined carbohydrates, and rigorous oral hygiene.  FDA-approved prescription 
treatment of the condition includes cevimeline or pilocarpine to increase salivary 
production and hydroxychloroquine to improve overall symptoms of affected patients.  
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While these therapies are effective, they are often not long-term solutions and slow, not 
stop, glandular deterioration.  Thus the search for more efficacious medications to treat 
this condition continues.(48) 
1.3  Diagnosis  
The establishment of a definitive clinical diagnosis for SS has remained an 
elusive goal, in light of its non-specific clinical symptoms and a lack of both specific and 
sensitive lab findings.  The American–European Consensus Classification Criteria has 
improved the diagnosis dilemma in clinical trials,(49) but a definitive diagnostic and 
disease severity marker is still needed.  Recent investigations into serum and salivary 
biomarkers have been undertaken to address this issue, from analysis of macromolecular 
structures such as whole intra and/or extracellular receptors themselves to 
micromolecular structures such as genomic analysis.  The findings from these studies 
may help elucidate etiological mechanisms and provide subsequent novel strategies to 
treat this disease.(50)  Notably, alterations in the type 1 interferon pathway have been 
demonstrated in SS, a feature that it shares with only systemic lupus erythematosus, 
dermatomylsitis, and psoriasis.  This pathway has been demonstrated to be upregulated 
in pSS patients and blockade of this pathway may be an important future therapy for 
treatment of SS.(51)   
1.4 Immunopathegensis of sjögren’s syndrome 
In healthy patients, normal immune function requires a coordination of both the 
innate and acquired arms of the immune system.  In many disease states a deficiency or 
hyperactivity of one pathway adversely affects the function of the other and leads to 
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development of clinical disease in the patient, as seen in SS.   SS is characterized by B-
lymphocyte hyperactivity and is evident on laboratory examination of serum by elevated 
amounts of gamma-globulins which includes a variety of autoantibodies.  The 
lymphocytic infiltrate around the exocrine glands consists of mainly CD4+ T-
lymphocytes (70%), with smaller amounts of B-, CD8+ T-, and  CD17+ T-
lymphocytes.(52)  Recent investigations of inflammatory mediators and immune cells 
themselves have been undertaken to explore what contribution, if any, the given 
molecule or cell has on B-cell expression and their effects on SS induction, progression, 
and resolution.     
Levels of TNF-alpha in the tears and circulation of SS patients are elevated, 
indicating a possible role in pathogensis of the disease.(53)  Besides its known pro-
inflammatory roles, TNF-alpha is known to be a direct inducer of cell-death, and in SS 
the cytokine has been shown to be localized around salivary epithelial cells.(54)  
However, clinical trials of two different TNF-alpha blocking medications (Infliximab 
and Enteracept) have shown mixed results in treating SS in vivo.  Infliximab is a 
monoclonal antibody that binds to TNF-alpha directly and impairs the molecules ability 
to agonize its respective receptor.  Enteracept is a fusion protein consisting of a human 
TNF-alpha receptor linked to an Fc IgG1 molecular tail.  TNF-alpha binds to the TNF-
alpha receptor end of the drug and once bound is cleared from the body by phagocytes 
after recognition of the Fc region, and subsequent opsonization and clearance of 
endogenous TNF-alpha.  Small uncontrolled trials with Infliximab on SS patients 
resulted in decreased symptoms after one year of treatment along with restoration of 
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normal distribution of aquaporin-5 to the cell membrane of salivary acinar cells.  
Aquaporin-5 was previously demonstrated to be down-regulated in SS, and is necessary 
for proper fluid transport into the salivary ducts.(55)  Larger-scale randomized 
controlled clinical trials demonstrated no beneficial outcomes when compared to 
placebo.(56)  Likewise, pilot studies on Enteracept were shown to be ineffective in 
improving symptoms in a small scale study of SS patients.(57),(58)   
Following case reports of development of SS following treatment for hepatitis-C, 
investigators explored the potential role of endogenous anti-viral molecules, mainly 
interferon-alpha, in SS patients.(59)  Their investigations found that increases in mRNA 
expression for IFN-alpha corresponded with increases in B-cell activating factor (BAFF) 
in salivary gland cells taken from SS patients compared to controls.  When these same 
cell populations were exposed to other cytokines, an increase in BAFF expression did 
not occur, suggesting a key role for the signaling of interferon-alpha in the disease 
process.(60)  However, clinical treatment of primary SS patients with interferon-alpha 
supplementation has shown improvement in salivary flow (61) along with and increased 
levels of aquaporin-5 on the cell membrane of parotid gland cells.(62)  Clearly 
interferon-alpha levels are altered in SS, but to what extent it determines disease 
presence or severity is unknown and the cell-culture and clinical studies have 
contradictory findings.   
Treatment involving B-cell depletion with Rituximab has shown promise.  
Rituximab is a monoclonal antibody that recognizes CD20, an extracellular molecule 
found only on B-cells.  Small pilot studies revealed reductions of lymphocytic infiltrates 
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and lymphoepithelial lesions.  T-lymphocyte populations were decreased as well.  Also, 
acinar structures returned to normal appearance in some patients.(63, 64)  In clinical 
trials, the efficacy of B-cell depletion directly corresponded to the remaining residual 
glandular function present when the therapy was started, meaning that the therapy was 
more effective in patients who had less pre-existing salivary gland damage from the 
disease.  Symptoms of decreased fatigue and other comorbid conditions along with 
increases in salivary flow were demonstrated in all patients with remaining salivary 
gland function at the start of the study.  More investigation of this drug’s effect on 
affected patients may be of great value in future treatment of the disease.(64)    
It has previously been shown that B-cell activating factor (BAFF) is upregulated 
in SS and correlates with titers of anti-SS-A and anti-SS-B antibodies.(65)  BAFF is also 
overexpressed in salivary glands of patients with SS.(66)  After previous studies with B-
cell depletion with rituximab, it was realized that there was increased BAFF expression 
on blood monocytes.  This led to the discovery of a negative feedback system that B-
cells exert on BAFF, and with a loss of this signal from B-cell depletion therapy, levels 
of BAFF increased.(66)  The concentration of BAFF seems to determine the rate of B-
cell repopulation as well as the rate of reappearance of memory B-cells in the circulation 
and peripheral tissues.(67)    
Monoclonal antibodies targeting co-stimulatory bonds between antigen 
presenting cells and CD8+ T-cells, are under investigation.  Salivary gland epithelial 
cells in SS have been demonstrated to express HLA class II and co-stimulatory 
molecules and may function as antigen-presenting cells in pSS, besides dendritic cells 
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and B cells.  Interfering in co-stimulation in pSS could, theoretically, inhibit both 
systemic and local autoimmune responses in pSS.  Abatacept, a fusion molecule of IgG–
Fc and cytotoxic T-lymphocyte antigen 4, modulates CD28-mediated T-cell co-
stimulation and a controlled trial with abatacept in pSS has been undertaken but the 
results are not published to date.(68)  More studies looking at various putative 
biomarkers are being reported using a proteonomics approach, but much more 
investigation is needed to fully characterize the molecules involved in the initiation, 
progression, and treatment of SS.(69)   
The initiation and underlying etiology of SS is complex and multifactorial, with 
suspected contributions from any one or a combination of the following events:  viral 
infection, aberrant activation of B- and T-lymphocytes, cytokine profiles favoring 
survival and multiplication of defective cell lines.  Recent studies on monoclonal 
antibody therapies have revealed much about the etiology of SS by characterizing how 
patients respond when contributions from a given cytokine or cell is blocked.  TNF-
alpha has been demonstrated to be of questionable significance in pathology of SS, with 
mixed results obtained in small pilot studies and larger randomized controlled studies.  
Interferon-alpha has had similar mixed results but is likely to be involved in BAFF 
signaling and as such merits further investigation.  B-cells are the major player in the 
disease progression of SS and BAFF signaling is suspected to be involved in 
repopulation of auto-reactive B-cells.  From a treatment efficacy standpoint, the disease 
duration is most important in predicting therapeutic benefit.  The disease duration 
dictates the amount of gland destruction and subsequent loss of salivary flow, and 
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treatment aimed at increasing or restoring lost flow by reversing the source of glandular 
destruction will not be beneficial if there is little or no residual function of the affected 
gland(s).(64) 
1.5 Periodontal disease 
 Periodontal disease has been demonstrated in numerous studies to be bacterial in 
origin, with development and maintenance of a complex bacterial biofilm extending 
subgingivally on the roots of the teeth.  In the supragingival areas, gram positive, aerobic 
bacteria predominate, with the bacterial population(s) becoming more anaerobic and 
gram (-) in nature as you progress apically down the root surface.  Gram (-) bacteria 
possess lipopolysaccharide (LPS), which is highly recognized and bound by innate 
immune cells.(70),(71)  Binding of LPS causes activation of the innate immune system, 
specifically polymorphonuclear cells (PMNs) and macrophages.  Activated PMNs and 
macrophages release a variety of lytic enzymes and cytokines.  These cytokines amplify 
the inflammatory response by priming localized gingival cells (fibroblasts, gingival 
epithelial cells, etc) to release matrix metalloproteinases (MMPs) and target the acquired 
immune system to the site of infection.  IL-1 beta, IL-6, and TNF-alpha have been 
associated with recruitment of pro-inflammatory cells, and are upregulated in the saliva 
of individuals with periodontitis.(72)  Six bacterial clusters were described by Socransky 
et al. in subgingival biofilms and related to structural characteristics of the biofilm 
extending away from the tooth surface and consist of the yellow, purple, green, orange, 
red, and blue.  The yellow cluster is composed of the Streptococcus species including S. 
sanguis and S. oralis and the purple cluster consists of Actinomyces odontolyticus and 
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Veillonella parvula.  The yellow and purple clusters are thought to be early colonizers 
and express ligands that allow for attachment to surfaces found in the host’s subgingival 
environment (cementum, gingival epithelial cells, enamel pellicle) and facilitate 
attachment to the subgingival microenvironment of other species.  The green cluster 
consists of Capnocyopha spp, Campylobacter concisus, Eikenella corrodens, and 
Actinomyces actinomycemcomitans.  The orange cluster consists of Fusobacterium spp, 
Prevotella spp, Micromonas micros (aka Peptostreptococcus micros), Campylocabeter 
spp, Eubacterium spp, and Streptococcus constellatus.  The red cluster consists of 
Porphyromonas gingivalis, Tanerella forsythia, and Tanerella denitcola and the blue 
cluster consists of Actinomyces species.  The orange and green clusters are thought to be 
a bridge between the early colonizers and the more virulent members of the red cluster, 
since they can bind to the already present members of the yellow and purple cluster 
bacteria and members of the red cluster.(73)  Specific gram negative bacteria have been 
implicated in the etiology of periodontal destruction, and will be further reviewed below.   
 Actinobacter actinomycetem (AA) is a small, nonmotile, gram-negative, 
saccharolytic, capnophilic, round-ended rod.  It was first suspected as a major 
contributor to periodontal destruction by its frequent detection in subgingival samples 
from patients with localized aggressive periodontitis (previously juvenile periodontitis) 
(74-77) and the fact that most subjects with localized aggressive periodontitis have an 
exaggerated serum antibody response to this pathogen when challenged.  ((78-80).  
Furthermore, successful treatment of these patients was associated with elimination 
and/or reduction in the AA levels recovered in the saliva, whereas failures were 
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associated with inability to lower counts of AA. ((81-83)  AA produces a number of 
damaging by-products, including a leukotoxin(84), is able to induce periodontal disease 
in animal experiments.(85), and can invade human gingival epithelial cells and escape 
host-immune detection.(86-88)  Also, increased concentration of AA were recovered 
from sites undergoing progressive attachment loss (up to 2mm in 3 months) in human 
subjects.  The collective evidence suggests that AA is a particularly virulent organism to 
the attachment apparatus around teeth, and may be a main etiologic contributor in 
localized aggressive periodontal disease.(89, 90)  
 Porphyrmonas gingivalis (Pg) is a gram-negative, anaerobic, nonmotile, 
asaccharolytic rod.  It is a member of the black-pigmented bacteroides group and 
member of the red complex family.  Pg has long been associated with chronic 
periodontal disease and (91) produces a wide array of virulence factors, including 
collagenase, multiple proteases, and endotoxin.  Early investigations indicated that Pg 
was rarely recovered from samples of periodontally healthy subjects, but was a frequent 
finding in destructive periodontal disease.  Like AA, in successfully treated sites, an 
elimination and/or reduction of Pg is often found in recurrent sites after treatment. ((92-
94)  Antibody studies have reliably demonstrated that most subjects undergoing 
attachment loss exhibit elevated antibodies to antigens of Pg.  Animal studies in dogs 
and mokeys have revealed that ligature induced periodontitis occurs with a coincident 
increase in Pg.(95)  Pg also has the ability to invade human gingival epithelial cells in 
vitro (96, 97) and has been recovered in epithelial cells recovered from the periodontal 
pocket.(98) 
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 Like Pg, Prevotella intermedia (Pi) is gram-negative, anaerobic, nonmotile, 
asaccharolytic rod and is also a member of the black-pigmented bacteroides.  Pi has been 
demonstrated to be elevated in number in acute necrotizing ulcerative gingivitis (ANUG) 
(99) and chronic periodontitis.(100).  This species appears to have a number of similar 
virulence factors like Pg, including fimbriae specific for gingival epithelial cell-surface 
targets, allowing for internalization of the bacteria.   
 Tannerella forsythia (Tf) is a gram-negative, anaerobic, spindle-shaped, highly 
pleomorphic rod and is a member of the red complex family.  It is extremely slow 
growing in-vitro, but it’s growth may be enhanced by co-culturing with Fusobacterium 
nucleatum.(101) and the addition of N-acetylmuramic acid (102).  Tf is often recovered 
from patients with chronic periodontal disease and from sites actively undergoing 
attachment loss.(103, 104)  Increasing numbers of Tf have been shown to be strongly 
correlated with increasing pocket depth(103, 105).  Also, refractory sites after treatment 
display a higher level of Tf and that it is the most commonly observed species in or on 
epithelial cells recovered from periodontal pockets.(105)  Serum antibody to Tf is 
elevated in patients with chronic periodontal disease, and may be extremely elevated in 
refractory periodontitis.(106)   
1.6 Sjögren’s syndrome and periodontal disease 
The periodontal status of SS patients has been studied previously, with mixed 
findings.  In a studies by Kuru et al. (evaluated primary and secondary SS patients) and 
Jorkjend et al. evaluated secondary SS patients only), the periodontal status of SS 
patients in terms of clinical attachment level, probing depths, bleeding on probing, 
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plaque index, and bacteriological profiles were no different from age and sex-matched 
controls.  They found that secondary SS patients had significantly more missing teeth, 
but the periodontal status of the teeth they had was no different from controls. (107, 108)  
Shiodt et al. again found no differences in all periodontal parameters in their study of 
only primary SS patients compared to controls.(109)  Boutsi et al. found no increased 
risk for developing periodontal disease in their study of primary and secondary SS 
patients, although they did find that SS patients had better oral hygiene and more 
frequent dental visits.(110)  In contrast, Antoniazzi et al. studied the periodontal status of 
primary and secondary SS patients compared to healthy age and sex-matched controls, 
and also measured the amount of interleukin 1-beta in their gingival crevicular fluid 
(GCF).  They found that patients with SS had increases in all measured periodontal 
parameters including bleeding on probing, probing depth, and clinical attachment level 
compared to healthy controls.  Also, they demonstrated that secondary SS patients had 
higher levels of periodontal disease than primary SS patients.  Primary SS patients had 
significantly lower levels of IL1-beta in their GCF than patients with secondary SS or 
control patients.(111)  Seck-Diallo et al. also found significant increases in inflammation 
(as measured by the gingival index of Sillness and Loe) and had a calculated odds ratio 
of 5.5 for developing periodontal disease after their study of 103 patients with SS 
compared to healthy controls.(112)  Another study by Najera et al. demonstrated an odds 
ratio of 2.2 for developing the disease in SS patients.(113)  The mechanism for increased 
susceptibility to periodontal disease in SS patients, if any indeed exists, is under 
investigation currently.  Pers et al. investigated the salivary levels of BAFF and 
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correlated them to periodontal findings in SS patients compared to patients with clinical 
signs of xerostomia but did not have SS.  They found that SS patients have increased 
levels of salivary BAFF compared to other dry mouth patients without SS, and that the 
levels of salivary BAFF correlated with increased probing depths in SS patients.(67)  
Scardina et al., using microangioscopy, determined that the microvasculature in the 
gingiva of SS patients was altered compared to healthy controls, and postulated that a 
decrease in local microcirculation would predispose this patient group to periodontal 
disease.(114)  It has been shown previously from studies in the periodontal literature that 
progressive periodontal disease is mediated by B-cells.  After clinical gingivitis 
develops, a T-cell mediated condition, the progression to periodontal disease occurs 
when the inflammatory infiltrate switches from T-cell dominated to B-cell dominated 
lesion.(115)  In SS, increased levels of salivary BAFF coupled with decreased 
vascularity of the periodontal complex would favor development of clinical periodontal 
disease due to alterations in normal immune function (hyperactive B-cell dominated 
lesions) and blood supply.  In summary, previous investigations have yielded 
contradictory findings about the prevalence of periodontal disease in both primary and 
secondary SS patients and the risk for developing periodontal disease once diagnosed 
with SS.  Plausible molecular explanations exist if SS does in fact favor clinical 
periodontitis, but the issue is unclear and needs to be investigated further. 
1.7 Toll-like receptors 
TLRs are highly conserved pattern recognition receptors found in humans.  They 
recognize pathogen-associated molecular patterns (PAMPs) such as LPS, peptidoglycan, 
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double stranded RNA, and bacterial DNA and allow for first-line activation of the innate 
immune system in response to infection.(116)  To date, there have been 10 TLRs 
identified in humans.  
 In the gingiva, TLRs have been identified on gingival epithelial cells, gingival 
fibroblasts, osteoclasts, endothelium, osteoblasts, cementoblasts, and periodontal 
ligament fibroblasts.  TLR4 is the only TLR that is present on each of the above cell 
types in the gingival tissues, and binds LPS present on the cell membrane of gram(-) 
bacteria, and is responsible for bacterial mucosal immunity.  TLR4 is a localized to the 
cell membranes of these gingival cells as well as PMNs, macrophages, and natural killer 
cells.  Once TLR4 binds LPS, it activates the innate immune system effector cells 
directly (in the case of TLR4 on leukocytes) or indirectly (in the case of TLR4 bound to 
gingival epithelial cells or fibroblasts) by promoting proinflammatory cytokine release 
and causing migration of the innate immune effector cells through chemotactic 
stimuli.(117)  The presence of LPS in the periodontium induces an influx of immune 
cells to clear the infection, and in the process of clearing the infection, bone and the 
supporting structures of the teeth are destroyed from the host of proteolytic enzymes and 
free radicals released from the inflammatory and local area cells.  A previous study had 
found that TLR4 was elevated in the saliva of adults diagnosed with chronic 
periodontitis.(118)  Also, it has been shown that there are soluble TLR4 receptors in 
saliva that mediate macrophage activity and TNF-alpha secretion.(119)  Overexpression 
of TLR4 could cause an exaggerated pro-inflammatory response and lead to increased 
periodontal destruction; conversely, defective TLR4 function and/or localized blockade 
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of the TLR4 could lead to decreased destruction compared to healthy individuals.  The 
activation of TLR4 in the gingival epithelial cells lining the gingival sulcus also leads to 
stimulation and maturation of area dendritic cells, which process area bacterial antigens 
and present them to both the innate and acquired immune systems, causing a further 
influx of inflammatory cells and periodontal destruction.(117)   
 TLRs have been identified in SS patients.  Ittah et al. demonstrated the presence 
of TLR3 and TLR7 in salivary gland epithelial cell cultures of SS patients.  Both TLR3 
and TLR7 are responsible for recognizing viral components.  TLR3 is an extracellular 
receptor that recognizes double stranded RNA and TLR7 is an intracellular endosomal 
receptor that recognizes single stranded RNA.  When the cell cultures were stimulated 
with double single and double stranded RNA and interferon-alpha (another anti-viral 
mediator), high levels of BAFF were excreted by these cells regardless of stimulatory 
source.  This finding that stimulation of anti-viral pathways resulted in high levels of 
BAFF secretion.  These findings provide more evidence that SS may be initiated by viral 
infection (not clear) and that malfunctions in viral immune mechanisms may 
inadvertently trigger BAFF expression and cause subsequent B-cell proliferation.(120)  
Furthermore, recent evidence indicates that a synergism exists between TLRs and B-cell 
receptors (BCRs) in activation of the B-cell itself.  When TLRs and BCRs are 
crosslinked by a common antigen, such as LPS (the ligand for TLR4), the B-cell may 
become activated without additional co-stimulation from area immune cells or 
cytokines.(121)   Other cell culture studies from labial minor salivary glands from SS 
patients and controls demonstrated increased expression of TLRs 2, 3, and 4, and when 
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stimulated with their respective ligands, increases in IL-6 production was produced from 
the cell cultures.(122)   Also, in a study that measured mRNA expression for TLRs 1, 2, 
3, and 4 by salivary gland epithelial cells from SS patients, an increase in expression was 
found for mRNA for the genes encoding TLRs 1, 2, and 4 compared to control 
data.(123)  In summary, recent studies have found that TLR levels are elevated in cell 
culture studies of salivary gland epithelium from SS patients, specifically TLRs 1, 2, 3, 
4, 7, and 9.  TLR4 is a good candidate to study any molecular correlation between SS 
and periodontal disease because TLR4 is secreted in a soluble form in the saliva(119) 
and is upregulated in patient groups that have either SS(122) or chronic periodontal 
disease.(118)  Analyzing salivary and serum levels of TLR 4 in SS patients may 
correlate with an increased risk of developing periodontal disease in this patient 
population and warrants further investigation.   
1.8 Toll-like receptors and other autoimmune diseases 
TLRs are the first line defense in humans for protection against microbial 
challenge, they have also been implicated in the development of many inflammatory and 
immune diseases, which are not thought to be directly related to bacterial or viral 
infection.(124)  This property of TLRs is believed to be from their ability to recognize 
host-derived mediators released during the course of diseases.  Through their ability to 
activate antigen presenting cells, TLRs provide a bridge between the innate and adaptive 
immune response.(125).  The ubiquitous distribution of TLRs and changes in their 
signaling both with each other and the host cells have been implicated in altered 
susceptibility to infection as well as autoimmune disease.(126) 
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Rheumatoid arthritis (RA) is an autoimmune disease primarily associated with 
inflammation of the synovial membranes and subsequent destruction of adjacent 
cartilage and bone.  TLR ligands have been demonstrated to be significantly elevated in 
RA synovial fluid and serum.(127)  Specifically, expression of TLR2 and TLR4 is 
increased in RA-fibroblast-like synoviocytes (FLS).  TLR2 and TLR4 ligands can 
induce receptor activator of nuclear factor-kappa beta ligand (RANKL) in RA-FLS and 
promote osteoclastic differentiation in the synovium of RA positive patients.(128)].  
Furthermore, TLR2 activation in RA-FLS by TLR2 ligands causes an induction of 
vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) causing 
inflammation directly by activation of local inflammatory mechanisms and indirectly by 
aberrant angiogenesis.(129)  In adjuvant-induced, zymosan-induced, and streptococcal 
cell wall-induced arthritis in animal models, TLR2 can induce and/or exacerbate 
pathogenesis.(130).  Activation of TLR2 with peptidoglycan or bacterial lipopeptide 
causes nuclear factor kappa beta (NF-kb) translocation and increases expression of pro-
inflammatory cytokines, adhesins, matrix metalloproteinases, and chemokines.(131).  
Heat shock protein bacteria 8 (HSPB8), a proposed TLR4 agonist, has been found to be 
highly expressed in the synovial tissue of RA patients and likely to be released during 
subsequent synovial inflammation.  The release of HSPB8 into the synovial environment 
could lead to continuous activation of area inflammatory cells, amplifying synovial 
inflammation and providing a positive feedback mechanism to exacerbate the disease.  
Ex-vivo cultures of human synovial cultures from human patients with RA was shown to 
have TLR2 and TLR4 present in the cultured media and responsive to exogenous 
 22 
 
ligands.(132)  More importantly, signaling mediated by the pan-TLR adaptor Myeloid 
differentiation factor 88 (MyD88) and  MyD88 adapter-like toll-interleukin 1 receptor 
domain containing adaptor protein (Mal/TIRAP), which is utilized by both TLR2 and 
TLR4, is involved in spontaneous production of cytokines and MMPs in RA synovial 
membranes.  Additionally, human RA synovial membrane cultures release factors that 
stimulate macrophages in a MyD88- and Mal-dependent mechanism.  In conclusion, 
TLR2 and TLR4 can both protect the host against infection, but also may promote the 
inflammatory cascade in RA by their interactions with exogenous and endogenous 
ligands present in situ.  
Experimental autoimmune encephalitis (EAE) is the animal equivalent of 
multiple sclerosis in humans, a common inflammatory demyelinating disease of the 
central nervous system (CNS).  Within the CNS, resident glial cell activation causes an 
inflammatory cascade that can lead to tissue destruction, neurologic deficits, and 
demyelination of neuronal cell membranes.  Recently, TLR agonists of TLR2, TLR4, 
TLR9 have demonstrated adjuvant properties in EAE,.(133, 134) providing a mechanism 
of limiting autoimmune responses in the CNS by negative regulation of TLR pathways.  
In a rodent experiment, rats immunized with a combination of myelin basic protein 
peptide (MBP), CpG-Oligodeoxynucleotide (ODN) in incomplete freund’s adjuvant 
(IFA) or LPS in IFA did not develop EAE.  However, rats immunized with a 
combination of MBP, CpG-ODN AND LPS developed clinical EAE.   In the same 
experiment, it was observed that spleen cells proliferated and secreted interferon-gamma 
in response to MBP, and caused secretion of IL-12p40 and IL-6 in response to CpG-
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ODN and LPS.  However, rats immunized with MBP, CpG-ODN, and Poly(I:C), a 
TLR3 ligand, did not develop EAE.  Collectively, this study demonstrated that different 
combinations of TLR agonists can induce or protect the host from EAE.(135)   In a 
follow-up study, wild type and TLR2 double knockout mice developed EAE in a similar 
time course of disease onset and severity after inoculation with myelin oligodendrocyte 
glycoprotein (MOG) peptide emulsified in complete freund’s adjuvant (CFA).  In 
contrast, under the same exposures, mice that are MyD88 double knockout are 
completely EAE resistant and TLR9 double knockout mice develop EAE but both the 
onset is slower and the severity is reduced.  Thus, both TLR9 and MyD88 are required 
for normal EAE induction and progression.  Stimulation of TLR3 by Poly(I:C) 
suppresses demyelination in EAE and suppression is associated with an induction and 
increase of endogenous interferon beta (IFN-B) and chemokine (C-C motif) ligand 2 
(CCL2)-monocyte chemoattractant protein 1 (MCP-1).  That study demonstrated that 
preferential activation of the MyD88-dependent, type 1 interferon-inducing TLR 
pathway may block the progression of tissue specific autoimmune disease.(136)  Also, 
activation of TLR3 and TLR4 by their respective ligands, dsRNA and LPS, consistently 
induces secretion of C-X-C motif chemokine 10 (CXCL10) by human microglial cells.  
CXCL10 has been implicated as a major chemoattractant of T-lymphocytes in the MS 
lesion.(137, 138)  The above studies have provided a plausible mechanism for T-cell 
infiltration in EAE via a TLR-dependent signaling cascade, but further study is needed 
before definite conclusions may be drawn.   
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Myocarditis is a major cause of sudden death in adolescents and young adults 
from sudden heart failure.  A large portion of these cases are believed to be caused by 
cardiac myosin acting as an auto-antigen.  In mice, dendritic cells primed with a cardiac-
specific self peptide induce CD4+ T-cell mediated myocarditis.  After the acute 
myocarditis resolved, these mice developed heart failure, and further stimulation of 
TLRs resulted in relapse of inflammatory cell infiltration in the heart.  Also, injection of 
damaged syngeneic cardiomyocytes induced myocarditis in mice if TLRs were activated 
in vivo. (46). Protein kinase C-e (PKC-e)-deficient mice failed to succumb to 
experimental autoimmune myocarditis (EAM), but administration of the TLR9 ligand 
CpG restored EAM in PKC-e-deficient mice.  It is believed the mechanism was from 
administered CpG directly restoring cell proliferation signals in TLR9-expressing T-
lymphoctyes.  Therefore, TLR mediated signaling in mice is adequate to overcome the 
normal regulatory signals of PKC and cause proliferation of a T-cells and cause the 
development of autoimmunity.(139)  In another murine model, coxsackie virus infection 
was found increase expression of TLR4 on mast-cells and macrophages immediately 
following infection.  TLR4 signaling can also increase acute myocaridits and elevate the 
production of inflammatory cytokines in cardiac tissue.(140)  Coxsackie B virus (CBV) 
infection is believed to be a main culprit in the development of myocarditis associated 
with inflammatory heart disease death in young adults.  Although these viruses are 
cytopathic, their RNA can persist in myocardium and contribute to a chronic 
inflammatory cardiomyopathy that is believed to be mediated through TLR8 and TLR7, 
but these claims require further investigation.(141)  In conclusion, myocarditis is usually 
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an acute condition with fatal and/or debilitating outcomes.  TLR-dependent pathways 
have been demonstrated to be a plausible mechanism for a healthy immune system going 
rogue and attacking the myocardial cells, with often times fatal outcomes.   
Hepatitis is defined as inflammation of the liver and may be caused by liver 
injurty by toxins, autoimmune attack from the host, and microbial and/or viral infection.  
There are several different forms of hepatitis, but the main forms are caused by three 
viruses, hepatitis A, B, and C viruses respectively.  Hepatitis C virus (HCV) infection 
usually causes a persistent inflammatory state of the liver via the host’s immune system 
and usually ends with sclerosis and/or cancer of the organ.  Recently, a correlation 
between the expression of TLR2, 3, and 6 in peripheral blood mononuclear cells 
(PBMC) and the severity of inflammation in the liver has been discovered in human 
chronic hepatitis C subjects.(142)  Also, it has been shown that RNA levels for TLRs 2, 
4, 5,6, 7, 8, 9, and 10 were increased in HCV-infected human monocytes and T-cells.  
TLR4 was only increased in T-lymphocytes, while TLR5 was selectively increased in 
monocytes.(143)  TLR3 recognizes double stranded RNA and induces the production of 
type 1 interferon to help combat the perceived viral infection.  In vitro, when the 
expression of TLR3 is suppressed in hepatocytes transfected with HCV, a continuous 
HCV infection is evident presumably due to decreased ability to combat viral infection 
in these cell lines.(144)   Furthermore, in HCV infection, dendritic cell expression of 
TLR2 is reduced and TLR2-stimulated dendritic cells are less competent in stimulating 
T-cell proliferation in vitro and combating HCV, thus providing evidence that TLR2 
may also be an important mechanism to protect the host from HCV-mediated 
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pathogenesis.(145)  In murine models, macrophages the expression of HCV 
nonstructural proteins NS3, NS3/4A, NS4B, or NS5A was found to impair activation 
and signaling of TLR2, TLR4, TLR7, and TLR9 pathways in macrophage cell lines.  
NS5A and MyD88 interact via the interferon sensitivity-determining region (ISDR) and 
inhibits cytokine production from macrophages.  Under normal conditions, TLR2-
mediated pathways are turned on by HCV core and NS3 proteins, and requires homo- or 
heterodimerization with TLR1 or TLR6 in humans.(146-148)  In chronic HCV infection 
in humans, there is a diminished number and function of HCV-reactive T-cells and 
antigen presenting cells and both cell types react with reduced function when stimulated 
with TLR ligands compared to wild-type cells from healthy hosts.(149)    
Immunotherapy is the main treatment modality for chronic HCV infection, which is 
causes problematic side effects and is only efficacious in roughly 50% of patients.  
Recently, it has been demonstrated that systemic administration of the TLR7 agonist 
isatoribine has a significant anti-viral effect and improves serum biomarkers with fewer 
and less severe systemic side effects.(150)  Furthermore, in another murine model 
affected with Hepatitis B virus (HBV), ligands for TLR3, TLR4, TLR5, TLR7, and 
TLR9 cause reduced HBV replication in hepatocytes within 24 hours of their systemic 
administration in an interferon-dependent manner.  The ability of TLR ligands to 
upregulate antiviral molecules at the site of infection may represent a novel, powerful 
therapy treat chronic hepatits infections.(151) 
TLRs present on renal cells help coordinate and amplify host immune responses 
to kidney infection by recognition of endogenous molecules released from injured cells 
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and may contribute to acute injury to tubular cells and provide and adjuvant effect on 
renal inflammation(152)  In a murine model, cultured renal tubular epithelial cells 
express TLRs 1-4, and TLR6 constituitively.  When stimulated with LPS, TLRs 2-4 
were upregulated and inflammatory cytokines were secreted in a dose-dependent manner 
by these cells.(153)  TLR2 was detected in renal tubule, vascular, glomeruli, and 
medullary renal cells in human and murine renal cells.  Mice deficient in TLR2 were 
more protected from ischemic renal injury than mice deficient in MyD88, demonstrating 
a plausible role for a TLR2-dependent/MyD88-independent pathway(s) that regulate 
renal injury during ischemia.(154)  Further evidence came from a murine study in which 
a TLR2 ligand was given at time of immunization and caused profoundly increased 
nephrotoxic nephritis by promoting hyperactive adaptive immune responses against 
renal cells.(155)  Other TLRs, such as TLR7 and TLR9 have been implicated in antigen-
induced immune complex glomerulonephritis and lupus nephritis.(156, 157)  Mice 
deficient in TLR9 display increased production of autoantibodies and acceleration of 
lupus nephritis compared to wild-type mice.(158)  Furthermore, cultured proximal 
tubular cells display increased TLR9 when stimulated with immune complexes from sera 
from human patients with systemic lupus erythematosus.  Other studies with MyD88 
knockout mice displayed that MyD88 contibutes to the pathogenesis of TLR-mediated 
injury to renal cells.  Also, TLRs have been demonstrated to be involved in transplant 
tolerance and rejection of grafted organs.  In conclusion, TLR-mediated pathology in 
renal cells has been demonstrated in human and animal studies, and may provide an 
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interesting target for therapies in the future, however these pathways are in their infancy 
of medical understanding.(159, 160) 
Systemic lupus erythematosus (SLE) is characterized by production of 
autoantibodies against a relatively narrow range of nuclear antigens by auto-reactive 
plasma cells.  These autoantibodies form immune complexes that deposit in tissues of 
the skin, kidneys, and other organs and induce inflammation.  A growing role for TLR-
mediated contributions to the pathology of this disease are being elucidated, however 
under different conditions, they may be either a protective or damaging partner to the 
host with respect to SLE-associated pathology.   Specifically, TLR5 and TLR7 
signalling have been shown to enhance the inflammatory damage from SLE.(161, 162)  
A stop codon polymorphism in the gene endcoding TLR5 has been recently identified in 
humans that protects humans from development of SLE.  Subjects with this 
polymorphism produce significantly lower levels of inflammatory cytokines compared 
to wild-type individuals.(161)  In murine models, duplication of TLR7 enhances 
autoimmune disease in SLE-prone mice.  Mice that are deficient in TLR7 but have had 
experimental SLE induced, display decreased lymphocyte activation and serum IgG 
responses, thereby improving the symptoms of SLE.(163)  Other TLRs, such as TLR9 
have a controversial role in SLE induction.(163, 164)  In murine studies, TLR9 deficient 
mice display enhanced SLE-pathology compared to wild-type mice. Without TLR9, 
activated lymphocytes and plasmocytoid dendritic cells increased in number and 
displayed elevated levels of serum IgG and interferon alpha.(163)  It has been 
hypothesized that TLR9’s protective effect may be due to the ability of certain anti-
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dsDNA antibodies to clear endogenous cellular debris thereby reducing the available 
substrate for anti-nuclear auto-antibodies.(165)  TLR9 can be stimulated by endogenous 
hypomethylated DNA in addition to it’s normal bacterial substrate.  Like other studies, 
MyD88-dependent and independent pathways in SLE models have been shown to co-
regulate TLR-mediated pathways.  TLR9/MyD88 signaling is required for a switch to 
production of pathologic auto-antibodies in murine models of SLE,(166) and in TLR9 
deficient mice, the generation of anti-dsDNA and anti-chromatin autoantibodies in 
inhibited.  In contrast to TLR9, mice deficient in TLR3 does not inhibit formation of 
auto-antibodies to either DNA- or RNA-antigens.(164)  Thus, TLR signaling can induce 
and/or reduce autoimmunity in SLE models and elucidation of more TLR-mediated 
pathways is a promising goal of future therapies to treat this debilitating disease.(167)  
In conclusion, the complex interplay of TLRs with endogenous and exogenous 
ligands has the capacity to bring about a protective or inductive reaction and trigger 
and/or exacerbate many different inflammatory states.  In addition to those mentioned 
above, diabetes mellitus types 1 (168) and 2 (169), autoimmune uveitis (170, 171), and 
the process of aging (172, 173), have all been investigated and confirmed inflammatory 
changes involving a collage of TLR-modulated signaling to both accelerate and/or 
ameliorate the conditions.  SS, being an inflammatory condition as well, is highly likely 
to have multiple TLR-mediated mechanisms for the induction, progression, and arresting 
of the condition and warrants further investigation.   
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1.9 Salivary analysis in disease states 
 Previous studies have successfully analyzed saliva for determining disease states 
(HIV, hepatitis, bacteremias), hormonal levels, cancer status, and drug usage.(174)  
Salivary analysis of periodontal infections has been useful in determining bacterial 
profiles, indirect determinations of cellular damage by examining enzymatic levels 
associated with apoptosis/necrosis (aspartate and alanine aminotransferases, lactate 
dehydrogenase, creatine kinase, alkaline and acidic phosphatases, and g-glutamyl 
transferase), and degree and type of immune response by analysis of immunoglobulin 
type and numbers.(175)  Serum components such as drug, drug metabolites, 
immunoglobulins, complement proteins, and hormones also reach the saliva, usually 
through gingival crevicular fluid outflow.  Recently, studies analyzing the salivary and 
plasma levels of TLR2 and TLR4 have been performed on patients with chronic 
periodontitis.  It was found that TLR4 was significantly elevated in both plasma and 
serum in periodontal patients, but TLR2 was elevated only in the plasma of periodontal 
patients compared to healthy controls.  Therefore, TLR4 is present in detectable 
quantities in control patients, but is increased in patients with chronic periodontal disease 
and may be a useful diagnostic biomarker of treatment efficacy and/or disease status in 
future studies.(118)    
1.10 Serologic analysis in disease states 
Blood analysis has long been useful for diagnosing a variety of disorders, from 
diabetes mellitus to malignancies.  Almost all of the secretions including, lacrimal and 
salivary, are derived from the bloodstream.  When blood is analyzed and allowed to clot, 
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the clear supernatant that forms is the serum component, and contains no blood cells or 
clotting factors.  Serum does, however, contain various other proteins that do not 
participate in the clotting process, various electrolytes, hormones, drugs and drug 
metabolites, antidodies, antigens, and can carry numerous types of microbial and/or viral 
intruders and their metabolites if present in the patient’s blood.  In the context of 
periodontal disease, serologic analysis been useful in determining immunologic, 
bacteriologic, and inflammatory mediator profiles, and how these profiles change in the 
face of different treatment modalities.(176, 177) 
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CHAPTER II 
 
COMPARISON OF SOLUBLE TOLL-LIKE RECEPTOR 4 IN PATIENTS WITH  
 
SJÖGREN'S SYNDROME, A CASE-CONTROL STUDY 
 
2.1 Synopsis 
 
 This cross-sectional study examined potential differences in concentration of 
Toll-like receptor 4 (TLR4) in serum and citric acid-stimulated saliva from patients with 
Sjögren’s Syndrome (SS) and healthy age-, sex-, and periodontal disease matched 
control patients.   
Salivary function was stimulated with 5.0 mLs of 2% citric acid, and whole 
saliva samples were obtained.  Full-mouth clinical periodontal measurements were 
recorded from 21 SS patients and 22 unaffected control patients.  Salivary and plasma 
TLR4 concentrations were determined by enzyme-linked immunoassays in 20 patients 
per study group.  Data were tested statistically as appropriate for the data distribution.   
No statistical difference in age, body mass index (BMI), salivary TLR4 
concentrations, or clinical periodontal measurements were evident between either group.  
Salivary flow rates were significantly lower (P<0.001) whereas plaque % (p=0.048) and 
serum TLR4 concentrations (p=0.011) were significantly higher  in SS patients.  
The present ﬁndings support a hypothesis that a hyperinflammatory systemic 
state, as seen in SS patients, can independently raise serum TLR4 concentration in the 
absence of periodontal disease and may be important in the induction and / or 
progression of SS-mediated pathophysiology in affected patients.   
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2.2 Introduction 
 
 SS is an autoimmune exocrinopathy and classically affects the salivary and 
lacrimal glands.  Approximately 2-4 million people in the United States are affected by 
the condition, with women diagnosed nine times more often than men.  SS is classified 
as either primary or secondary, depending on the absence or simultaneous presence of 
another autoimmune disease (AI).(1)  A definitive biomarker or serum finding signifying 
positive disease status has remained elusive, and most diagnoses are made later in the 
disease process and are usually classified by the American-European Consensus 
Classification Criteria from 2002.  This classification system assesses six categories and 
includes ocular and oral symptoms, ocular signs, histopathology of minor salivary gland 
biopsies, salivary gland involvement, and autoantibodies upon serologic analysis. A 
definitive diagnosis is made if four of six items are positive as long as the histopathology 
and serologic findings are positive.  Alternatively, if three out of the four objective items 
(clinical tests vs. symptoms) are positive a diagnosis may be made.(2)  A revised 
definition was made by the American Academy of Rheumatology in 2012.  This 
definition requires two out of three objective features be met for a positive diagnosis and 
assesses serologic findings, minor gland histopathology, and ocular signs.(3)  Consistent 
oral manifestations include increased caries rate, dryness, increased fungal infections, 
painless enlargement of salivary glands, altered salivary flow, difficulty in swallowing, 
speaking, chewing, and alterations in taste.  Biopsies of minor salivary glands are 
considered the “gold standard” in SS diagnosis. SS is diagnosed by the presence of 
pathologic changes consisting of a T-lymphocyte predominated inflammatory cell 
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infiltrate around periductal tissues with a resulting loss of acinar cells and secretory 
function.(4)  Nonspecific serum changes in SS patients may  include 
hypergammaglobulinemia, elevated total protein and erythrocyte sedimentation rate 
(ESR), decreased white blood cell count, persistent elevated  rheumatoid factors, and 
autoantibodies anti-sicca-syndrome-A (Anti-SS-A, also known as Ro) and Anti-SS-B 
(also known as La).  SS also predisposes patients to an increased risk of developing 
lymphoma(s) with a reported 4000% higher incidence than the general population..(5)  
Treatment is palliative in nature and often includes sialagogues to increase salivary flow; 
however, these medications have many potential side-effects and do not slow the 
destruction of the salivary glands.  New therapies, such as TNF-alpha blocking agents or 
B-cell depletion therapy show promise but need more study before routine clinical 
application.(6) 
 Chronic periodontal disease is among the most common oral diseases in humans.  
It is believed to be initiated by a complex interplay between bacterial biofilm 
colonization in the periodontal pocket and the host immune response and is marked by 
inflammatory changes in the supporting structures of the teeth.  Initially, reversible 
gingival inflammation, gingivitis, is characterized by a largely T-lymphocyte infiltration 
of the soft tissues causing edema and erythema with an increase in gingival bleeding.  If 
allowed to progress, gingivitis may remain stagnant or may progress to 
periodontitis,where the infiltrate switches to a plasma cell dominated lesion.  The 
immune system is activated  and an inflammatory destruction of the attachment 
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apparatus and bone around the teeth ensues(7).  However, the exact mechanism of the 
inflammatory signaling process is unknown.   
TLRs are highly conserved pattern recognition receptors found in humans.  They 
recognize pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharides 
(LPS), peptidoglycans, and various bacterial and/or viral genetic materials such as 
double stranded RNA. This allows for first-line activation of the innate immune system 
in response to infection.(8)  To date, there have been 11 TLRs identified in humans.  
TLR4 is membrane bound and secreted in a soluble form, recognizes LPS, and is 
responsible for mucosal surveillance of gram(-) bacterial infection.  In the oral cavity, it 
is found on epithelial cells, gingival fibroblasts, osteoclasts, endothelial cells, 
osteoblasts, cementoblasts, and periodontal ligament fibroblasts it activates local 
polymorphonuclear neutrophils (PMNs) and macrophages in the face of gram(-) 
infection.  Previous in vitro cell-culture studies have indicated that SS patients secrete 
more inflammatory cytokines and have increased mRNA levels of TLR4 when 
stimulated with LPS.(9), (10) 
In the gingiva, TLRs have been identified on gingival epithelial cells, gingival 
fibroblasts, osteoclasts, endothelium, osteoblasts, cementoblasts, and periodontal 
ligament fibroblasts.  TLR4 is the only TLR that is present on each of the above cell 
types in the gingival tissues.  It binds LPS present on the cell membrane of gram(-) 
bacteria and is responsible for bacterial mucosal immunity.  TLR4 is also localized to the 
cell membranes of PMNs, macrophages, and natural killer cells.  Once TLR4 binds LPS, 
it activates the innate immune system effector cells directly (in the case of TLR4 on 
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leukocytes) or indirectly (in the case of TLR4 bound to gingival epithelial cells or 
fibroblasts) causing proinflammatory cytokine release and causing migration of the 
innate immune effector cells through chemotactic stimuli.(11)  Immune cells infiltrate 
the affected areas to clear the infection, and in the process bone and the supporting 
structures of the teeth are destroyed from the host of proteolytic enzymes and free 
radicals released from the inflammatory and local area cells.  A previous study had found 
that TLR4 was elevated in the saliva of adults diagnosed with chronic periodontitis.(12)  
Also, it has been shown that there are soluble TLR4 receptors in saliva that mediate 
macrophage activity and TNF-alpha secretion.(13)  Overexpression of TLR4 could cause 
an exaggerated pro-inflammatory response and lead to increased periodontal destruction; 
conversely, defective TLR4 function and/or localized blockade of the TLR4 could lead 
to decreased destruction compared to healthy individuals.  The activation of TLR4 in the 
gingival epithelial cells lining the gingival sulcus also leads to stimulation and 
maturation of area dendritic cells, which process area bacterial antigens and present them 
to both the innate and acquired immune systems, causing a further influx of 
inflammatory cells and periodontal destruction.(11)   
TLRs have been identified in SS patients.  TLR3 and TLR7 have been identified 
in salivary gland epithelial cell cultures of SS patients, both of which are responsible for 
viral recognition.  Stimulation of these cells with the respective ligands of TLR3 and 
TLR7 caused an elevated release of B-cell activating factor (BAFF), causing B-cell 
proliferation.  These findings provide evidence that SS may be initiated by viral 
infection and that malfunctions in viral immune mechanisms may inadvertently trigger 
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BAFF expression and cause subsequent B-cell proliferation.(14)  Furthermore, recent 
evidence indicates that a synergism exists between TLRs and B-cell receptors (BCRs) in 
activation of the B-cell itself.  When TLRs and BCRs are cross-linked by a common 
antigen, such as LPS (the ligand for TLR4), the B-cell may become activated without 
additional co-stimulation from area immune cells or cytokines.(15)   Other cell culture 
studies from labial minor salivary glands from SS patients and controls demonstrated 
increased expression of TLRs 2, 3, and 4, and when stimulated with their respective 
ligands, increases in IL-6 production was produced from the cell cultures.(9)   Also, in a 
study that measured mRNA expression for TLRs 1, 2, 3, and 4 by salivary gland 
epithelial cells from SS patients, an increase in expression was found for mRNA for the 
genes encoding TLRs 1, 2, and 4 compared to control data.(10)  In summary, recent 
studies have found that TLR levels are elevated in cell culture studies of salivary gland 
epithelium from SS patients, specifically TLRs 1, 2, 3, 4, 7, and 9.  TLR4 is a good 
candidate to study any molecular correlation between SS and periodontal disease 
because TLR4 is secreted in a soluble form in the saliva(13) and is upregulated in patient 
groups that have either SS(9) or chronic periodontal disease.(12)  Analyzing salivary and 
serum levels of TLR 4 in SS patients may correlate with an increased risk of developing 
periodontal disease in this patient population and warrants further investigation.   
Saliva is a useful diagnostic fluid and has been used to determine disease states 
and assay cellular damage, cancer biomarkers, hormonal levels, and drug use.(16)  
Saliva is readily available and conveniently collected, and has previously been shown to 
contain inflammatory mediators collected from periodontal patients including 
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measurable amounts of TLR4 (12)  Whole saliva comes from exocrine glands of the oral 
cavity and contains inflammatory mediators of pooled sites from the oral cavity and may 
provide a useful assessment of general inflammation in contrast to gingivocrevicular 
fluid which is site-specific.(17) 
Blood analysis has long been the gold standard for diagnosing a variety of 
disorders.  Almost all secretions of the lacrimal and salivary glands are derived from the 
blood.  When blood is collected and is allowed to clot, the clear supernatant that forms is 
the serum component, and contains no cells or clotting factors but does contain 
electrolytes, hormones, drugs and drug metabolites, antibodies, antigens, bacteria, 
viruses, and bacterial and viral metabolites.  Serum analysis has been used to assess 
immunologic, bacteriologic, and inflammatory mediator profiles and how these values 
change with treatment with respect to periodontal disease.(18, 19)  
To the best of our knowledge, neither salivary nor circulating levels of TLR4 
have been analyzed in patients with SS.  Our hypothesis is that salivary and serum levels 
of TLR4 are increased in SS patients due to upregulation by stimuli generated from 
receptor crosstalk involved in the signaling cascades of induction and progression of SS 
compared to age-, sex-, and periodontal disease status-matched control patients.     
2.3  Materials and methods 
 
2.3.1 Study population 
 
 A total of 43 subjects were included in the study.  The study protocol was 
approved by the Institutional Review Board of Texas A&M Health Science Center 
(TAMUHSC), and conducted in full compliance with ethical principles, including the 
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Helsinki Declaration of 1975, as revised in 2000.  Twenty-one non-smoking patients 
with diagnosed SS and twenty-two, non-smoking, age and sex-matched control patients 
were recruited from the staff and faculty of Texas A&M University-Baylor College of 
Dentistry (TAMUBCD).  Patients were recruited from October 2012 to August 2013 
from the Stomatology and Salivary Dysfunction Clinic.  The American-European 
Consensus Classification Criteria was used to make a positive diagnosis (49), and was 
used because many of these patients were diagnosed prior to the 2012 diagnostic 
revision by the American Academy of Rheumatology.(178)  The study protocol was 
explained and written informed consent was obtained from each individual before 
salivary and venous blood collection, and periodontal measurements were made.  
Medical and dental histories were obtained.  All patients had 16 teeth present with at 
least two molars.  Patients with diabetes mellitus, hepatitis, malignancies, oral and/or 
mucosal ulcerations, clinically detectable oral/pharyngeal candidiasis, pregnant and/or 
lactating females, those under the age of 18, visible oral/mucosal ulcerations, clinically 
detectable untreated odontogenic infections, or who had periodontal therapy six months 
previously were excluded from the study (Table 1).  Periodontal disease was assessed by 
the clinical case definitions proposed by the Centers for Disease Control working group 
for use in population based surveillance of periodontitis.(179)  An absence of 
periodontitis was confirmed if patients did not have ≥ 2 interproximal sites with a 
clinical attachment loss (CAL) of  ≥3 mm or ≥ 2 sites with interproximal probing depths 
(PD) of  ≥ 4mm (excluding mild, moderate, and severe periodontitis).(180)  After data 
collection from SS patients, age and sex-matched control patients were recruited and 
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were excluded if any of the above conditions existed or if the periodontal status differed 
from the SS-matched patient in an attempt to exclude the effect periodontal disease may 
have on serum and salivary levels of TLR4. 
2.3.2 Salivary collection 
Stimulated salivary collection was completed as described by Navazesh et 
al.(181)  Briefly, patients were instructed to brush and floss their teeth, rinse, and fast for 
two hours immediately before salivary collection.  At the time of collection, patients 
rinsed with 10.0 mL’s of sterile deionized water for one minute.  Salivary flow was 
stimulated with a five second swish of 5.0 mLs of 2% citric acid.  After one minute, the 
patients expectorated any accumulated secretions into a separate container that was 
discarded.  Then, expectorated whole saliva was collected on ice into pre-weighed, pre-
chilled sterile 50.0 mL polypropylene tubes until a total volume of 5.0 mL’s was reached 
or twenty minutes had elapsed.  Salivary collection was timed and weighed in order to 
calculate a salivary flow rate.  Saliva was immediately processed by centrifugation 
(800g) for 10 minutes at 4ºC and aliquoted into 500 uL amounts with sterile water.  The 
samples were immediately frozen and stored at -80ºC until the sample collection period 
ended and thawed immediately before assays.  
2.3.3 Serum collection 
Ten mLs of venous blood was taken from the antecubital fossa by standard 
venipuncture with Vacutainers®.k  The Vacutainer was inverted five times immediately 
after collection and allowed to sit undisturbed for one hour per manufacturer’s 
recommendations.  Serum was separated from blood by centrifugation at 12,000 rpm for 
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ten minutes and stored at -80ºC until the sample collection period ended and thawed 
immediately before assays.  
2.3.4  Periodontal measurements 
 After saliva and serum collection, clinical periodontal measurements including 
PD, CAL, presence of  bleeding upon probing (BOP), and plaque from six sites (mesio-
buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) of all 
teeth were recorded with a UNC15 periodontal probe.‡  Furcations (Glickman 
classification) and mobility (Miller classification) were assessed with a Nabors probe 
and bi-digital manipulation.  CAL was assessed from the cementoenamel junction (CEJ) 
to the base of the probable pocket and BOP was positive if it occurred within 30 seconds 
after probing.  Finally, a disclosing agent†† was applied to the teeth per manufacturer’s 
recommendations, and plaque was recorded dichotomously as present or absent at six 
sites per tooth.  Measurements were recorded by two calibrated examiners (JB, HP).  
Examiners were calibrated before the study began and again three months into the study 
by comparing full mouth probing exam values.  Demographic and periodontal 
measurements were reported for all patients in the study (n=21 SS, n=22 control).   
2.3.5 Measurement of toll-like receptor 4 in serum and salivary samples 
One test sample and two control sample were randomly selected and used for 
calibration purposes and were not used for ELISA analysis.  The remaining 20 test 
samples and 20 control samples were selected for analysis with TLR4 enzyme-linked 
immunosorbent assay (ELISA) kits§ following the manufacturer’s protocol.  Samples 
were not diluted.  The concentrations of TLR4 in the saliva and serum samples were 
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determined by comparing the average sample optical density (OD) reading to 
concentrations from the assay standard curve.  For samples that had an optical density 
above the maximum detectable range, a linear equation was derived from the standard 
curve and measured OD values were used to derive the concentration of TLR4.  The 
lower detection thresholds for the TLR4 assay was 0.016 ng/mL, the upper detection 
limit was 10.0 ng/mL.   
2.3.6 Statistical analysis 
 A power analysis was performed from a previous study, and with a power of 
80% and alpha at 0.05, the minimum number of subjects to detect a difference was 
twenty per group.  Shapiro-Wilk normality tests were performed on all numerical 
variables with the null hypothesis that the variable in question was normal versus the 
alterative that the variable was not normal. For variables that were normal, a t-test was 
performed between the control group and the SS group. For variables that were not 
normal, Mann-Whitney was used, and to settle disputes caused by ties in Mann-Whitney, 
jittering was used and repeated (Monte-Carlo) with 10,000 permutations. The p-value 
was averaged over the 10,000 permutations, creating a simulated p-value, and reported. 
Correlation coefficients were found using Pearson’s correlation coefficient between 
variables, and correlation coefficients greater than 0.6 were considered to be noteworthy. 
Finally, for the binary data if the patient visited the dentist in the past 6 months (1 = Yes 
and 0 = No), the Fisher’s Exact Test was used because this data was structured as a 2x2 
contingency table.  
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The number of patients taking an individual medication was counted and summed 
according to the pharmacological category of that particular drug (e.g. antihypertensives, 
psychologics, biologics, etc.). A percent difference was calculated as  
                  
 
(                                                                 )
                              
 
The distribution of the number of drugs taken by patients was tested for normality using 
the Shapiro-Wilk statistic, which indicated that the distribution was in fact not normal. 
Therefore, the total number of drugs used by the SS group and control group was 
analyzed using a Mann-Whitney test to see if there was a significant difference.  
Serum and saliva were analyzed for TLR4 using Mann-Whitney U test.  The first 
two consecutive patients that completed the study protocol were excluded for calibration 
and training purposes.  One more patient was randomly eliminated three months into the 
study and used for re-calibration purposes.  Thus, twenty patients per group remained.  
All statistical tests were performed at alpha = 0.05.  All statistical tests were completed 
with SPSS (IBM).   
2.4 Results 
2.4.1 Clinical analyses 
 Inter-examiner differences were not statistically different for measured clinical 
variables (Table 2).  Clinical variables and mean/median values of clinical 
measurements are outlined in Table 3.  The healthy control group exhibited no 
significant differences with regard to age, BMI, PD, CAL, furcation involvements, and 
mobility as the SS group, but had significantly less plaque (p<0.041) than the SS group.  
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The male/female ratio was 3:18 for the SS group and 2:20 for the control group, with no 
significant difference in sex distribution between either group.  Salivary collection mass 
and salivary flow rates were significantly different, with the SS group having 
significantly lower salivary flow (p<0.001) than the control group.  No significant 
difference was observed in frequency of dental visits, with both groups reporting they 
received dental care more than twice annually.  Prescription drug information is 
displayed by drug class in Table 4.  Some patients were on multiple classes of drugs to 
treat the same condition (e.g. hypertension), therefore the total number of drugs was 
tabulated per class per patient group instead of the number of patients taking a drug in 
each group.  As expected, SS patients were on significantly more prescription 
medication (6.61 medications/patient vs. 2.36 medications/patient in the control group).  
SS patients took significantly more anti-malarial medication (hydroxychloroquine) and 
medication for analgesia, gastro-esophageal reflux disease (GERD), psychiatric 
conditions, dry mouth, insomnia, thyroid dysfunction, and hormone replacement therapy 
(HRT).  No significantly different amounts of medication were taken to treat allergies, 
hypertension, or hyperlipidemia.  Significantly fewer SS patients took no medication 
compared to control patients (2 SS patients, 8 control patients).  In addition to the tables 
listed above, correlations between variables were calculated.  Significant correlations 
were determined to be correlations with     . Notable correlations were Flow with 
Saliva Mass (r=.863), Flow with Collection Time (r=-.759), Average PD with Average 
CAL (r=.604), PD > 5 mm with Collection Time (r=.655), and number of Grade 1 
Furcation with Grade 2 Furcation (r=.617).  Salivary volume (lower SS group, p < .001), 
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Salivary Flow (lower SS group, p < .001), and plaque index (higher SS group, p = .049) 
were all statistically significantly different.  Finally, a z-proportion test was performed to 
see if the 3:18 ratio of men-women in the SS group of the study reflected the population 
proportion of 1:9 accurately. The result of the test was        , indicating there was 
no significant difference between the study and the true population sex ratio. 
2.4.2 Salivary and serum toll-like receptor 4 concentration 
 There was no statistically significant difference in salivary TLR4 levels between 
patient groups (p = 0.312), however; serum TLR4 was significantly elevated in SS 
patients vs. controls (p =0.011) as seen in Table 5. 
2.5 Discussion 
 The present study compared salivary and serum values of TLR4 in patients with 
SS and with age, sex, BMI, and periodontal disease-matched control patients.  As 
expected, significant differences in salivary flow rates were found between groups.  The 
decreased salivary function in SS patients may account for this and consequently these 
patients were taking more sialagogue medications than control patients (14/21 SS 
patients, 0/22 control patients).  The loss of protective salivary functions, such as 
decreased clearance from diminished quantities of IgA, IgM, mucins, and salivary 
washing action possibly explains the higher plaque percentage scores observed in the SS 
patients in the present study.   
While no direct statement may be made on the prevalence of periodontal disease 
in SS patients from our study, it provides supporting evidence that SS is not a risk factor 
for periodontal disease because of our ability to recruit 22 patients that were 
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periodontally healthy with SS.  This is in agreement with Kuru et al. and Jorjend et al. 
who found no higher prevalence of periodontal disease in SS patients.(182)  Also, 
similar to a study by Boutsi et al., we found that SS patients visit their dentist more than 
recommended (>2 times/year) and tend have meticulous oral hygiene.  Even though 
supragingival plaque was statistically higher than control patients, bleeding on probing 
was less (although the difference was not statistically different) and frequent trips to 
their dental professionals for prophylaxis and reduction in the intra-oral bioburden may 
be protective in nature from developing periodontal disease in SS patients in the absence 
of normal salivary flow.  Also, the role of anti-inflammatory medication cannot be 
ignored as more SS patients were taking immunomodulating medications which may 
have masked clinical oral/gingival inflammation.   
 We found no differences in salivary concentrations of TLR4 between SS and 
control patients.  This was somewhat expected since we excluded patients with 
periodontal disease.  Periodontal disease, being a predominantly gram (-), anaerobic 
infection, provides antigens for both membrane-bound and soluble TLR4 and causes 
activation of the innate and consequently acquired immune responses.(116, 117)  
Without a suitable number of antigens in the absence of periodontal disease, it follows 
that TLR4 would not be expressed more than at a basal level for necessary surveillance 
of the oral cavity.  Also, the present study found salivary TLR4 concentrations of 2.650 
ng/mL and 2.364 ng/mL for the SS and control patients, respectively, in contrast to 
Buduneli et al.’s study who found 14.44 ng/mL average salivary concentration in healthy 
control patients.  This difference may be partially explained by the different methods of 
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salivary collection.  Both studies collected whole saliva, however, the present study 
utilized stimulated saliva with 2% citric acid and Buduneli’s study utilized unstimulated 
saliva by expectoration only.  Stimulated saliva differs in composition by its source, with 
approximately 50% coming from the parotid gland while unstimulated saliva is 
composed of ~20% parotid, 65% submandibular, 7-8% sublingual, and <10% from 
minor glands).(184)  The contribution of each major and collective minor salivary glands 
has on TLR4 concentration requires further study in disease and health in multiple age 
groups before definitive conclusions may be drawn.  Also, citric acid may chelate 
proteins, thus decreasing the amount of soluble TLR4 available for capture; however, the 
method of collection should have greatly reduced and/or eliminated this interference.  
Citric acid was used in the present study, despite its limitations, because it is one of the 
most potent stimulators of salivary flow, and was necessary to collect an adequate 
salivary volume in SS patients.  Furthermore, geographic differences in dietary 
composition, genetic factors, influence of medication, and age-related differences also 
partially explain the differences between our findings and those of Buduneli et al.  
Finally, ‘normal’ values of TLR4 in saliva are unknown.  To our knowledge, this is the 
only study that has described the concentration of TLR4 in stimulated human saliva in 
healthy and SS affected patients. 
Differences in serum TLR4 values may be explained by increased molecular 
crosstalk from autoimmune complexes potentially creating a hyperactive systemic 
immune state.  These findings are in agreement with in the vitro findings of Spachidou et 
al.(123), Kamachi et al. (122), and Berglova (121) that demonstrated increased 
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expression of TLR4 mRNA in salivary gland epithelial cells, increased expression of 
membrane-bound TLR4 complexes, and hyperactive B-lymphocyte function when 
challenged with LPS respectively.  Serum TLR4 concentrations of the control patients in 
the present study were lower than those reported in Budeneli et al. (0.840 ng/mL in the 
present study vs. 0.97 ng/mL in Budeneli et al.)  Like the salivary values, differences in 
geography and demographics, medication regimen, and patient age may potentially be 
the cause of a different result.  Again, ‘normal’ TLR4 serum concentration expression in 
health and disease in different age groups requires more investigation to define what a 
true normal/abnormal value is in health and disease.   
SS patients were on significantly more prescription medication than control 
patients, and took more anti-malarial medication (hydroxychloroquine), analgesics, 
HRTs, and medication to treat GERD, psychiatric conditions, dry mouth, insomnia, and 
thyroid dysfunction.  No differences were observed with frequency of patients taking 
medication to treat allergies, hypertension, or hyperlipidemia.  Also, only two SS 
patients were not taking any prescription medication whereas eight control patients did 
not take any.  Patients were not instructed to discontinue the use of any prescribed 
medication they currently were taking, as doing so would be unethical.  However, the 
local and systemic effects cannot be ignored and may have skewed our data.  For 
example, SS patients may in fact have more periodontal disease and inflammation than 
unaffected patients, as reported by Najera et al. (113), Seck-Diallo et al.(112), and 
Antoniazzi et al. (111), but the clinical presentation of inflammation as bleeding on 
probing was masked by immunomodulatory medication.  Also, stimulated salivary 
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secretion volume, secretion rate, and TLR4 concentration would probably be different in 
the absence of sialagogue medication in SS patients.  Interestingly, 9/21 SS patients were 
being treated with proton-pump inhibitors (PPIs) for GERD.  A recent in vitro study by 
Ubagai et al. reported that PPI’s decreased PMN function with respect to release of 
inflammatory mediators (various cytokines, TNF-alpha, TLR4) when challenged with 
LPS and found a down-regulation of all gene transcripts analyzed when the duration of 
treatment exceeded 3 hours.(184)  The effects of PPIs on TLR4 expression in the serum 
and saliva in vivo requires further study but the potential of PPI therapy  to influence our 
observed results exists and may have affected our findings.  Finally, the anti-malarial 
drug hydroxychloroquine has long been used for treatment of various rheumatic diseases 
and has potent immunomodulatory effects.  In vitro human cell-culture studies and 
murine models have demonstrated that hydroxychloroquine causes a down-regulation of 
TLR4 when challenged with LPS (185, 186).  The potential influence of this unique drug 
also could further contribute to the observed findings.  The systemic effect of medication 
regimens cannot be ignored in the present study and therefore the current findings should 
be interpreted with caution until there is further study on the independent and interactive 
effects of different medications on salivary and serum TLR4 concentrations.    
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CHAPTER III 
CONCLUSIONS 
3.1 Summary of findings 
The present study demonstrated that stimulated salivary flow rates are 
statistically significantly lower and plaque percentage is statistically significantly higher 
in SS patients than controls.  Also, SS patients on average visited their dental 
professional >2 times per year and enhanced dental care may have promoted good 
periodontal health in the absence of normal salivary function.  Furthermore, stimulated 
salivary concentrations of TLR4 were not statistically significantly different than control 
patients but serum concentrations of TLR4 were statistically significantly elevated 
compared to control patients.   
3.2 Conclusions 
These finding may represent an enhanced systemic inflammatory state and prove 
to be a useful marker to gauge the efficacy of a given therapeutic regimen.  The study 
could not control for the systemic and local effects of medications, and further 
investigation is needed to elucidate the "normal and abnormal" values of TLR4 in 
disease and health.   
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APPENDIX A 
 
TABLES 
Table 1.  American-European consensus classification of Sjögren’s syndrome (2)   
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Table 1. Continued 
 
Table 1:  American-european consensus classification of sjogren’s syndrome.(2)  
For primary SS, a positive diagnosis if four out of the six items are positive as long as 
either item IV or VI is positive.  Also, if three of the four objective criteria are positive 
(items III, IV, V, and VI), a positive diagnosis is  made.  For secondary SS, the presence 
of item I or item II plus any 2 from among items III, IV, and V may be considered as 
indicative of secondary SS.  
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Table 2. Exclusion and inclusion criteria 
 
Table 2:  Exclusion and inclusion criteria.  Subjects were excluded or included based 
upon the above parameters. 
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Table 3. Inter-examiner calibration 
 Buccal Palatal Total 
Percent Agreement 
(%) 
65.7 54.3 60.0 
T-test p-value .459 .122 .496 
ICC .628 .491 .558 
T-test p-value (Bias)  .229    (0.047) .519     (-
0.114) 
.750    (-0.033) 
Table 3:  Inter-examiner calibration.  Calibration statistics for buccal, palatal, and 
combined buccal and palatal (total).  From the table above, it is evident that both raters 
were similar. The total percent agreement was above 60%, and any differences were 1 
mm or less.  The total t-test for the raw difference between both raters was not 
significant (p-value = .496). Additionally, the t-test for bias was insignificant (p-value = 
.75). 
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Table 4.  Patient demographics and periodontal parameters 
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Table 4. Continued 
 
Table 4:  Patient demographics and periodontal parameters.  The single star (*) 
indicates a variable that was determined to be normal by Shapiro-Wilk statistic. For each 
normal variable the mean and standard deviations were reported. Additionally, a t-test 
was performed, and its associated p-value was reported.  For those not marked with a 
single star (*) or a double star (**), the median and interquartile range (IQR) was 
reported, as well as the p-value from the Mann-Whitney test, the final row (designated as 
“**”) represents the percent of patients who did visit the dentist within 6 months and the 
p-value from Fisher’s exact test was reported.   
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Table 5. Medication regimens per group 
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Table 5. Continued 
 
Table 5:  Medication regimens per group.  This table shows the aggregate number 
patients taking drugs and types of drugs.  The bolded numbers along with the bolded and 
capitalized category shows the total number of patients taking the drugs listed per the 
specific test group status. 
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Table 6. Salivary and serum toll-like receptor 4 concentrations 
 SS Patients 
n = 20 
Median (IQR) 
Control Patients 
n = 20 
Median (IQR) 
p-value 
Salivary TLR4 (ng/mL) 2.650 (1.80) 2.364 (1.54) 0.312 
Serum TLR4 (ng/mL) 0.987 (0.144) 0.840 (0.159) 0.011 
 
Table 6:  Salivary and serum toll-like receptor 4 concentrations.  Mann-Whitney U 
test found statistically significantly higher serum TLR4 concentration between SS and 
control patients (p=0.011).  8) 
3.025 (1.54).755 (0.14) 
 
 
 
 
